Whilst transdermal patch formulations represent an area of ongoing pharmaceutical research, no GLP-1 patches are currently licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) or approved by the National Institute for Health and Care Excellence (NICE) for use in the United Kingdom
Incorporating a balanced diet, regular physical activity, and behavioral changes enhances the benefits of these medications and supports long-term weight loss and maintenance
Nausea, diarrhea, vomiting, constipation, abdominal discomfort, indigestion, and reflux are among the most common side effects
GLP-1 activation, appetite control, thermogenesis, plus AMPK
As of January this year, California, New Hampshire, Pennsylvania and South Carolina ended Medicaid GLP-1 drug coverage for weight loss, and Michigan started restricting coverage to people classified as morbidly obese, meaning they have a body mass index above 40
Patients considering berberine should discuss this with their GP or pharmacist, particularly if they have existing medical conditions or take prescribed medications
